Literatura ACTA MEDICINAE 10/2019 Onkologie

Literatura ACTA MEDICINAE 10/2019 Onkologie 3 Očekávání nového algoritmu léčby pokročilého karcinomu ledviny prof. MUDr. Jindřich Fínek, Ph.D., MHA Onkologická a radioterapeutická klinika FN a LF UK, Plzeň 3 Použití molekulárněgenetických metod v klinické onkologii MUDr. Ľudmila Křížová prof. MUDr. Luboš Petruželka, CSc. Onkologická klinika VFN a ÚVN 1. LF UK, Praha 3 Karcinom děložního hrdla, screening, význam HPV a možnosti testování As. RNDr. Ing. Libor Staněk, PCTM synlab czech, s. r. o., ČR, Chirurgická klinika, 3. LF UK, Praha, Vysoká škola dravotníctva a sociálnej práce sv. Alžbety v Bratislavě prof. MUDr. František Mateička, CSc. Vysoká škola dravotníctva a sociálnej práce sv. Alžbety v Bratislavě 3 Nová éra v adjuvantní léčbě pokročilého melanomu MUDr. Ivana Krajsová, MBA Dermatovenerologická klinika VFN a 1. LF UK, Praha 4 Výsledky multifaktoriální analýzy pětiletého sledování pacientů zařazených do studií COMBI-v a COMBI-d MUDr. Eugen Kubala Onkologická klinika 1. LF UK a Thomayerovy nemocnice, Praha 4 Trastuzumab emtansin ve druhé linii HER2 metastatického karcinomu prsu: léčba, která není dostupná pro všechny potřebné pacienty prof. MUDr. Petra Tesařová, CSc. Onkologická klinika 1. LF UK a Všeobecné fakultní nemocnice, Praha 4 Současnost a výhledy v léčbě karcinomu prsu MUDr. Markéta Palácová Klinika komplexní onkologické péče, Masarykův onkologický ústav, Brno 4 Aktuální možnosti léčby karcinomu prsu MUDr. Zuzana Bielčiková, Ph.D. Onkologická klinika 1. LF UK a VFN, Praha 5 Vliv ribociclibu v kombinaci s endokrinní léčbou na celkové přežití u žen s karcinomem prsu Studie MONALEESA-7 MUDr. Jiří Slíva, Ph.D. Ústav farmakologie 3. LF UK, Praha 5 Nemetastatický kastračně rezistentní karcinom prostaty MUDr. Jana Katolická, Ph.D. Onkologicko-chirurgické oddělení FN u sv. Anny v Brně 6 Lorlatinib zařazení do aktuální léčebné praxe MUDr. Juraj Kultan Klinika plicních nemocí a tuberkulózy FN a LF UP v Olomouci 6 Nový algoritmus léčby pokročilého NSCLC doc. MUDr. Milada Zemanová, Ph.D. Onkologická klinika 1. LF UK a VFN, Praha 7 Co nového v imunoterapii na WCLC 2019 MUDr. Leona Koubková Pneumologická klinika UK 2. LF a FN Motol, Praha 7 Léčba kolorektálního karcinomu ve druhé linii Rozhovor Mgr. Dany Frantálové s MUDr. Radmilou Lemstrovou, doc. MUDr. Tomášem Büchlerem, Ph.D., MUDr. Petrou Klimčíkovou, MUDr. Jiřím Tomáškem, Ph.D., MUDr. Stanislavem Johnem a MUDr. Zdeňkem Linkem 7 Zkušenosti s bevacizumabem v první a druhé linii terapie pacientky s metastazujícím karcinomem rekta kazuistika MUDr. Michal Vočka Onkologická klinika, 1. LF UK a VFN, Praha 7 Tromboembolické komplikace u onkologických pacientů a jejich primární profylaxe prof. MUDr. Jan Kvasnička, DrSc. Trombotické centrum ÚLBLD a I. interní klinika VFN a 1. LF UK, Praha 8 Léčebné konopí MUDr. Marek Hakl, Ph.D. Centrum léčby bolesti, Medicinecare, s. r. o., Chirurgická klinika FN a LF MU, Brno 8 Možnosti léčby nádorové bolesti MUDr. Jan Lejčko Centrum pro léčbu bolesti Anesteziologicko-resuscitační kliniky FN Plzeň 8 Národní onkologické programy: klíč ke zlepšení onkologické péče Annual Cancer Media Summit

Literatura ACTA MEDICINAE 11/2019 Hematoonkologie 8 CAR-T lymfocyty v léčbě B-buněčných lymfomů MUDr. Pavel Otáhal, Ph.D. prof. MUDr. Marek Trněný, DrSc. I. interní klinika 1. LF a VFN, Praha 8 Immune checkpoint inhibitory v léčbě Hodgkinova lymfomu MUDr. Veronika Hanáčková doc. MUDr. Vít Procházka, Ph.D. Hemato-onkologická klinika, FN Olomouc a LF UP, Olomouc 9 Konjugované monoklonální protilátky v léčbě lymfomů MUDr. Jan Kořen I. interní klinika klinika hematologie, 1. LF UK a VFN, Praha 9 Léčba nehodgkinských lymfomů monoklonálními protilátkami v roce 2019 MUDr. David Belada, Ph.D. IV. interní hematologická klinika, FN HK a LF UK v Hradci Králové 9 Bispecifické protilátky v léčbě akutní lymfoblastové leukemie a lymfomů MUDr. Kamila Polgárová prof. MUDr. Marek Trněný, CSc. Interní klinika klinika hematologie, 1. LF UK a VFN, Praha 10 Lymfom z plášťových buněk ve světle nových poznatků doc. MUDr. Pavel Klener, Ph.D. I. interní klinika hematologie, VFN a 1. LF UK, Praha 11 Relabující lymfom z plášťových buněk léčený úspěšně ibrutinibem kazuistika MUDr. Juraj Ďuraš prof. MUDr. Roman Hájek, CSc. Klinika hematoonkologie, FN Ostrava, Klinika hematoonkologie, LF Ostravské univerzity, Ostrava 11 Ibrutinib v léčbě refrakterního lymfomu z plášťových buněk kazuistika MUDr. Heidi Móciková, Ph.D. Interní hematologická klinika FNKV a 3. LF UK, Praha 11 Použití ibrutinibu jako bridging k alogenní transplantaci krvetvorných buněk od haploidentického dárce a následné terapii reziduální nemoci po transplantaci u pacientky s vysoce nepříznivým průběhem lymfomu z plášťových buněk kazuistika MUDr. Veronika Válková, CSc. Ústav hematologie a krevní transfuze, Ústav klinické a experimentální terapie UK, Praha 11 Cílená terapie chronické lymfocytární leukemie MUDr. Jakub Trizuljak prof. MUDr. Michael Doubek, Ph.D. Interní hematologická a onkologická klinika, Lékařská fakulta a Fakultní nemocnice Brno, Středoevropský technologický institut (CEITEC) Masarykovy univerzity, Brno 12 Venetoklax opakované použití u nemocné s prognosticky nepříznivou chronickou lymfocytární leukemií MUDr. Jana Zuchnická Klinika hematoonkologie Fakultní nemocnice Ostrava 12 Léčba esenciální trombocytemie anagrelidem MUDr. Jiří Slíva, Ph.D. Ústav farmakologie 3. LF UK, Praha 13 Buněčná terapie u akutních leukemií MUDr. Jan Vydra Ústav hematologie a krevní transfuze, Praha 13 Diagnostika a terapie sekundárních protilátkových imunodeficiencí u hematoonkologických pacientů z pohledu imunologa MUDr. Tomáš Milota Ústav imunologie 2. LF UK a FN v Motole, Praha

Očekávání nového algoritmu léčby pokročilého karcinomu ledviny prof. MUDr. Jindřich Fínek, Ph.D., MHA Onkologická a radioterapeutická klinika FN a LF UK, Plzeň 1 Motzer, J. R. Tannir, N. M. McDermott, D. F.: Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med, 2018, 378, s. 1277 1290. 2 Motzer, R. J. Tannir, N. M. Dermott, D. F., et al.: Nivolumab plus ipilimumab versus sunitinib advanced renal-cell carcinoma. NEJM, 2018. 3 Choueiri, T. K. Halabi, S. Sanford, B. L., et al.: Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: The Alliance A031203 CA- BOSUN Trial. J Clin Oncol, 2017, 35, s. 591 597. 4 Rini, B. I. Plimack, E. R. Stus, V., et al.: Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med, 2019, 380, s. 1116 1127. 5 Motzer, J. R. Penkov, K. Haanen, J., et al.: Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med, 2019, 380, s. 1103 1115. 6 Motzer, R. J. Powles, T. Atkins, M. B., et al.: I Mmotion 151: A randomized phase iii study of atezolizumab plus bevacizumab vs sunitinib in untreated metastatic renal cell carcinoma (mrcc). J Clin Oncol, 2018, 36, s. 578 578. 7 www.sukl.cz Použití molekulárněgenetických metod v klinické onkologii MUDr. Ľudmila Křížová prof. MUDr. Luboš Petruželka, CSc. Onkologická klinika VFN a ÚVN 1. LF UK, Praha 1 Petruželka, L.: Které nádory jsou skutečně vzácné? Onkol Rev, 2018, 4. 2 Sawyers, C.: Targeted cancer therapy. Nature, 2004, 432, s. 294 297. 3 Petruželka, L.: Pohled na vývoj onkologie ve 3. tisíciletí. Klin Onkol, 2009, 22, s. 243 244. 4 MacConaill, L. E. Garraway, L. A.: Clinical implications of the cancer genome. J J Clin Oncol, 2010, 28, s. 5219 5228. 5 Jameson, J. L. Longo, D. L.: Precision medicine personalized, problematic, and promising. N Engl J Med, 2015, 372, s. 2229 2234. 6 Hyman, D. M. Taylor, B. S. Baselga, J.: Implementing genome-driven oncology. Cell, 2017, 168, s. 584 599. 7 Kurzrock, R. Giles, F. J.: Precision oncology for patients with advanced cancer: the challenges of malignant snowflakes. Cell Cycle, 2015, 14, s. 2219 2221. 8 National Laboratory of Enteric Pathogens, Bureau of Microbiology, Laboratory Centre for Disease Control: The polymerase chain reaction: An overview and development of diagnostic PCR protocols at the LCDC. Can J Infect Dis, 1991, 2, s. 89 91. 9 Mullis, K. Faloona, F. Scharf, S., et al.: Specific enzymatic amplification of DNA in vitro: the polymerase chain reaction. 1986. Biotechnology, 1992, 24, s. 17-27. 10 Tichopad, A., et al.: Standardized determination of real-time PCR efficiency from a single reaction set-up. Nucleic Acids Res, 2003, 31, s. e122. 11 Banda, M.: Detection of mutant RAS subpopulations in colorectal cancer patients. E Bio Medicine, 2015, 2, s. 280 281. 12 Jader, J. N. Sharif, S. B. Shakhinia, E.: Microsatellite instability in colorectal cancer. EXCLI J, 2018, 17, s. 159 168. 13 Wolff, D. J.: Fluorescence in situ hybridization (FISH). In: The Principles of Clinical Cytogenetics, 2013, s. 415 439. 14 Arbour, K. C. Riley, G. J.: Diagnosis and treatment of ALK positive NSCLC. Hematol Oncol Clin North Am, 2017, 31, s. 101 111. 15 Gutierrez, C. Schiff, R.: HER2: Biology, detection, and clinical implications. Arch Pathol Lab Med, 2011, 135, s. 55 62. 16 Albarello, L. Pecciarini, L. Doglioni, C.: HER2 testing in gastric cancer. Adv Anat Pathol, 2011, 18, s. 53 59. 17 Aitman, T. J.: Science, medicine, and the future: DNA microarrays in medical practice. BMJ, 2001, 323, s. 611 615. 18 Bernard, P. S. Wittwer, C. T.: Real-time PCR technology for cancer diagnostics. Clin Chem, 2002, 48, s. 1178 1185. 19 Chen, C. Y.: DNA polymerases drive DNA sequencing-by-synthesis technologies: Both past and present. Front Microbiol, 2014, 5, s. 305. 20 Bennett, S. T. Barnes, C. Cox, A., et al.: Toward the 1,000 dollars human genome. Pharmacogenomics, 2005, 6, s. 373 382. 21 Rizzo, J. M. Buck, M. J.: Key principles and clinical applications of next-generation DNA sequencing. Cancer Prev Res, 2012, 5, s. 887 900. 22 Kamps, R. Brandão, R. Bosch, B., et al.: Next-generation sequencing in oncology: genetic diagnosis, risk prediction and cancer classification. Int J Mol Sci, 2017, 18, s. pii: E308. 23 Mark, J. R. Kucherov, V. Pintauro, M., et al.: What is the clinical utility of next generation sequencing (NGS) in advanced urologic malignancies? J Clin Oncol, 2019, 37, suppl., s. 285 285. 24 Soukupová, J. Zemánková, P. Kleiblová, P., et al.: CZECANCA: CZEch CAncer panel for Clinical Application design and optimization of the targeted sequencing panel for the identification of cancer susceptibility in high-risk individuals from the Czech Republic. Klin Onkol, 2016, 29, suppl. 1, s. S46 S54. 25 Neumann, M. H. D. Bender, S. Krahn, T., et al.: ctdna and CTCs in liquid biopsy current status and where we need to progress. Comput Struct Biotechnol J, 2018, 16, s. 190 195. 26 Moorcraft, S. Y. Gonzalez, D. Walker, B. A.: Understanding next generation sequencing in oncology: A guide for oncologists. Crit Rev Oncol Hematol, 2015, 96, s. 463 474. 27 Stricker, T. Catenacci, D. V. T. Seiwert, T. Y.: Molecular profiling of cancer the future of personalized cancer medicine: A primer on cancer biology and the tools necessary to bring molecular testing to the clinic. Semin Oncol, 2011, 38, s. 173 185. 28 Subbiah, V. Kurzrock, R.: Universal genomic testing needed to win the war against cancer: Genomics IS the diagnosis. JAMA Oncol, 2016, 2, s. 719 720. 29 Wheler, J. Lee, J. J. Kurzrock, R.: Unique molecular landscapes in cancer: Implications for individualized, curated drug combinations. Cancer Res, 2014, 74, s. 7181 7184. 30 Slabý, O.: Technologie sekvenování nové generace: celogenomové, celoexomové a cílené hotspot sekvenování 2018, www.prolekare.cz. 31 Shyr, D. Liu, Q.: Next generation sequencing in cancer research and clinical application. Biol Proced Online, 2013, 15, s. 4. Karcinom děložního hrdla, screening, význam HPV a možnosti testování As. RNDr. Ing. Libor Staněk, PCTM synlab czech, s. r. o., ČR, Chirurgická klinika, 3. LF UK, Praha, Vysoká škola dravotníctva a sociálnej práce sv. Alžbety v Bratislavě prof. MUDr. František Mateička, CSc. Vysoká škola dravotníctva a sociálnej práce sv. Alžbety v Bratislavě 1 Dušek, L. Mužík, J. Kubásek, M., et al.: Epidemiologie zhoubných nádorů v České republice [online]. Masarykova univerzita, [2005], [cit. 2014 8-10]. Dostupný z WWW: http://www. svod.cz. Verze 7.0 [2007]. 2 De Sanjose, S. Quint, W. G. Alemany, L., et al.: Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol, 2010, 11, s. 1048 1056. 3 Tachezy, R. Mahelova, J. Salačova, M., et al.: Human papillomavirus genotype distribution in Czech women and men with diseases etiologically linked to HPV. PLoS One, 2011, 6, s. 21913. 4 Cibula, D. Petrželka, L., et al.: Onkogynekologie. Grada Publishing, Praha, 2009, s. 616. 5 Dundr, P. Němejcová, K.: Prekancerózy a karcinomy děložního hrdla. Doporučený postup pro bioptické vyšetření. Společnost českých patologů, www.patologie.info. 6 McCluggage, W. G.: New developments in endocervical glandular lesions. Histopathology, 2013, 1, s. 138 160. 7 Robová, H. Rob, L. Pluta, M., et al.: Guideline gynekologických zhoubných nádorů: Standard komplexní léčba časných stadií zhoubných nádorů děložního hrdla. Guideline C53 2013, www.onkogynekologie.com. 8 Sangrajrang, S. Laowahutanont, P. Wongsena, M., et al.: Human papillomavirus (HPV) DNA and mrna primary cervical cancer screening: Evaluation and triaging options for HPV-positive women. J Med Screen, 31. 7. 2019. 9 Vink, F. J. Meijer, C. J. L. M. Clifford, G. M., et al.: FAM19A4/miR124-2 methylation in invasive cervical cancer: A retrospective cross-sectional worldwide study. Int J Cancer, 7. 8. 2019. Nová éra v adjuvantní léčbě pokročilého melanomu MUDr. Ivana Krajsová, MBA Dermatovenerologická klinika VFN a 1. LF UK, Praha 1 National Cancer Institute. Surveillance, epidemiology and end results (SEER). 12/2018. 2 Leiter, U. Stadler, R. Mauch, C., et al.: Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT). Lancet Oncol, 2016, 17, s. 757 767. 3 Faries, M. B. Thompson, J. F. Cochran, A. J., et al.: Completion dissection or observation for sentinel node metastasis in melanoma. N Engl J Med, 2017, 376, s. 2211 2222. 4 Ives, N. J. Suciu, S. Eggermont, A. M. M., et al.: International melanoma meta-analysis collaborative group (IMMCG). Adjuvant interferon alfa for the treatment of high risk melanoma: an individual patient data meta-analysis. Eur J Cancer, 2017, 82, s. 171 183. 5 Eggermont, A. M. Chiarion-Sileni, V. Grob, J. J., et al.: Adjuvant ipilimumab versus placebo after complete resection of high risk stage III melanoma (EORTC 18071): a randomised, double blind, phase 3 trial. Lancet Oncol, 2015,16, s. 522 530. 6 Eggermont, A. M. Chiarion-Sileni, V. Grob, J. J., et al.: Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N Engl J Med, 2016, 375, s. 1845 1855. 7 Tarhini, A. A. Lee, J. S. Hodi, S., et al.: United states Intergroup E1609: A phase III randomized study of adjuvant ipilimumab (3or 10 mg/kg) versus high-dose interferon alfa 2b for resected high-risk melanoma. J Clin Oncol, 2019, 37, suppl., abstrakt 9515. 8 Weber, J. Mandala, M. Del Vecchio, H. J., et al.: Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med, 2017, 377, s. 1824 1835. 9 Eggermont, A. M. M. Blank, C. U. Mandala, M., et al.: Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med, 2018, 378, s. 1789 1801. 10 Long, G. V. Hauschild, A. Santinami, M., et al.: Adjuvant dabrafenib plus trametinib in stage III BRAF mutated melanoma. N Engl J Med, 2017, 377, s. 1813 1823. 11 Hauschild, A. Dummer, R. Schadendorf, D., et al.: Longer follow-up confirms relaps free survival benefit with adjuvant dabrafenib plus trametinib in patients with resected BRAF V600 mutant stage III melanoma. J Clin Oncol, 2018, 36, s. 3441 3449. 12 Schadendorf, D. Hauschild, A. Santinami, M., et al.: Effect on health-related quality of life (HRQOL) of adjuvant treatment with dabrafenib plus trametinib in patients with resected stage III BRAF mutant melanoma. J Clin Oncol, 2018, 36, suppl., abstrakt 9590.

Výsledky multifaktoriální analýzy pětiletého sledování pacientů zařazených do studií COMBI-v a COMBI-d MUDr. Eugen Kubala Onkologická klinika 1. LF UK a Thomayerovy nemocnice, Praha 1 Haluska, F. G. Tsao, H. Wu, H., et al.: Genetic alteration in signaling pathways in melanoma. Clin Cancer Res, 2006, 12, s. 2301 2307. 2 Menzies, A. M. Haydu, L. E. Visintin, L., et al.: Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma. Clin Cancer Res, 2012, 18, s. 3242 3249. 3 Long, G. V. Menzies, A. M. Nagrial, A. M., et al.: Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol, 2011, 29, s. 1239 1246. 4 Chapman, P. B. Hauschild, A. Robert, C., et al.: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med, 2011, 364, s. 2507 2516. 5 Hauschild, A. Grob, J. J. Demidov, L. V., et al.: Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet, 2012, 380, s. 358 365. 6 Robert, C. Karaszewska, B. Schachter, J., et al.: Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med, 2015, 372, s. 30 39. 7 Long, G. V. Stroyakovsky, D. K. Gogas, H., et al.: COMBI-d: a randomized, double-blinded, phase III study comparing the combination of dabrafenib and trametinib to dabrafenib and trametinib placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAFV600E/K mutation-positive cutaneous melanoma. J Clin Oncol, 2015, 33, suppl., abstrakt 102. 8 Robert, C. Grob, J. J. Stroyakovskiy, D., et al.: Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma. N Engl J Med, 2019, 381, s. 626 636. 9 Long, G. V. Grob, J. J. Nathan, P., et al.: Factors predictive of response, diseas progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials. Lancet Oncol, 2016, 17, s. 1743 1754. 10 Hamid, O. Robert, C. Daud, A., et al.: 5-Year survival outcomes in patients (pts) with advanced melanoma treated with pembrolizumab (pembro) in KEYNOTE-001. J Clin Oncol, 2018, 36, s. 9516, abstrakt. 11 Hodi, F. S. Kluger, H. Sznol, M., et al.: Durable, long-term survival in previously reated patients with advanced melanoma (MEL) who received nivolumab (NIVO) monotherapy in a phase I trial. Proc Am Assoc Cancer Res, 2016, 76, suppl., CT001, abstrakt. 12 Robert, C. Schachter, J. Long, G. V., et al.: 5-Year survival and other long-term outcomes from KEYNOTE-006 study of pembrolizumab (pembro) for ipilimumab (ipi)-naive advanced melanoma. Presented at the American Association for Cancer Research Annual Meeting, Atlanta, 29. 3. 3. 4. 2019, abstrakt. 13 Prieto, P. A. Yang, J. C. Sherry, R. M., et al.: CTLA-4 blockade with ipilimumab: longterm follow-up of 177 patients with metastatic melanoma. Clin Cancer Res, 2012, 18, s. 2039 2047. 14 Maio, M. Grob, J. J. Aamdal, S., et al.: Five year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in aphase III trial. J Clin Oncol, 2015, 33, s. 1191 1196. 15 Ugurel, S. Rohmel, J. Paolo, A., et al.: Survival of patients with advanced metastatic melanoma: the impact of novel therapies update 2017. Eur J Cancer, 2017, 83, s. 247 257. 16 Long, G. V. Weber, J. S. Infante, J. R., et al.: Overall survival and durable responses in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib combined with trametinib. J Clin Oncol, 2016, 34, s. 871 878. 17 Weide, B. Martens, A. Hassel, J. C., et al.: Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab. Clin Cancer Res, 2016, 55, s. 5487 5496. Trastuzumab emtansin ve druhé linii HER2 metastatického karcinomu prsu: léčba, která není dostupná pro všechny potřebné pacienty prof. MUDr. Petra Tesařová, CSc. Onkologická klinika 1. LF UK a Všeobecné fakultní nemocnice, Praha 1 Teicher, B. A. Doroshow, J. H.: The promise of antibody-drug conjugates. N Engl J Med, 2012, 367, s. 1847 1848. 2 Verma, S. Miles, D. Gianni, L., et al.: Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med, 2012, 367, s. 1783 1791. Současnost a výhledy v léčbě karcinomu prsu MUDr. Markéta Palácová Klinika komplexní onkologické péče, Masarykův onkologický ústav, Brno 1 Liedtke, C. Mazouni, C. Hess, K. R., e t al.: Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol, 2008, 26, s. 1275 1281. 2 Osborne, C. R. Kannan, L. Xie, X. J., et al.: Neoadjuvant chemotherapy for basal-like breast cancer cohort: clinical and pathological outcomes. Breast Cancer Res and Treat, 2006, 100, s. S53. 3 Dent, R. Trudeau, M. Pritchard, K. I., et al.: Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res, 2007, 13, s. 4429 4434. 4 Carey, L. A. Dees, E. C. Sawyer, L., et al.: The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res, 2007, 13, s. 2329 2334. 5 Haffy, B. G. Yang, Q. Reiss, M., et al.: Locoregional relaps and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol, 2006, 24, s. 5652 5657. 6 Cortazar, P. Zhang, L. Untch, M., et al.: Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet, 2014, 384, s. 164 172. 7 von Minckwitz, G. Untch, M. Blohmer, J. U., et al.: Definition and impact of pathological complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol, 2012, 30, s. 1796 1804. 8 Harbeck, N. Gluz, O.: Neoadjuvant therapy for triple negative and HER-2 positive early breast cancer. Breast, 2017, 34, s. S99 S103. 9 Denkert, C. von Minckwitz, G. Darb-Esfahani, S., et al.: Tumour-infiltrating lymphocytes and prognosis in different subyteps of breast cancer: a pooled analysis of 3771 patients terated with neoadjuvant therapy. Lancet Oncol, 2018, 19, s. 40 50. 10 Loi, S. Drubay, D. Adams, S., et al.: Tumor-infiltrating lymphocytes and prognosis: A pooled individual patient analysis of early-stage triple-negative breast cancers. J Clin Oncol, 2019, 37, s. 559 570. 11 Schmid, P. Adams, S. Rugo, H. D., et al.: Atezolizumab and nab-pacliatxel in advanced triple-negative breast cancer. N Engl J Med, 2018, 29, 379, s. 2108 2121. 12 Tolaney, S. M. Guo, H. Pernas, S., et al.: Seven-year follow-up of adjuvant paclitaxel and trastuzumab trial for node-negative, human epidermal growth factor receptor 2 positive breast cancer. J Clin Oncol, 2019, 37, s. 1868 1875. 13 Guarneri, V. Dieci, M. V. Bisagni, G., et al.: De-escalated therapy for HR+/HER2+ breast cancer patients with KI67 response after 2 weeks letrozole: resulsts of the PerELISA neoadjuvant study. An Oncol, 2019, 30, s. 921 926. 14 Rimawi, M. F. De Angelis, C. Contreras, A., et al.: Low PTEN levels and PIK3CA mutation predict resistence to enoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer. Breast Cancer Res Treat, 2018, 167, s. 731 740. 15 Pivot, X. Romieu, G. Debled, M., et al.: 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomized phase 3 trial. Lancet Oncol, 2013, 14, s. 741 748. 16 Earl, H. M. Hiller, L. Vallier, A. L., et al.: 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSE- PHONE): 4-year disease-free survival results of a randomise phase 3 non-inferiority trial. Lancet, 2019, 393, s. 2599 2612. 17 Conte, P. Frassoldati, A. Bisagni, G., et al.: Nine keks versus one aer adjutant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study. An Oncol, 2018, 29, s. 2328 2333. 18 Von Minckwitz, G. Huang, C. S. Mano, M. S., et al.: Trastuzumab emtansine for rezidual invasive HER2-positive breast cancer. N Engl J Med, 2019, 380, s. 617 628. 19 McCart Reed, A. E. Kalita-deCroft, P. Kutasovic, J. R., et al.: Recent advances in breast cancer research impacting clinical diagnostic practice. J Pathol, 2019, 247, s. 552 562. 20 Davies, C. Godwin, J. Gray, R., et al.: Relevance of breast cancer hormone receptors and other factors to the efficacy of adjutant tamoxifen: patient-level meta-analysis of randomized trials. Lancet, 2011, 378, s. 771 784. 21 Schiavon, G. Smith, I. E.: Status of adjutant endocrine therapy for breast cancer. Breast Cancer Res, 2014, 16, s. 206. 22 Turner, N. C. Ro, J. Andre, F., et al.: Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med, 2015, 373, s. 209 219. 23 Cristofanilli, M. Turner, C. N. Bondarenko, I., et al.: Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor positive, HER2-negative metastatic breast cancer, that progressed on previous endocrine therapy (PALOMA-3): final analysis of multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol, 2016, 17, s. 425 439. 24 Turner, N. C. Slamon, D. J. Jungsil, R., et al.: Overall survival with palbociclib and fulvestrant in advanced breast cancer. N Engl J Med, 2018, 379, s. 1926 1936. 25 Hortobagyi, G. N. Stemmer, S. M. Burris, H. A., et al.: Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus letrozole alone in hormone receptor-positive, HER2-negative advanced breast cancer. Ann Oncol, 2018, 29, s. 1541 1547. 26 Slamon, D. J. Neven, P. Chia, S., et al.: Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, HER2-negative advanced breast cancer: MONALEESA-3. J Clin Oncol, 2018, 36, s. 2465 2472. 27 Goetz, M. P. Toi, M. Campone, M., et al.: MONARCH 3: Abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol, 2017, 35, s. 3638 3646. 28 Sledge, G. W. Jr. Toi, M. Neven, P., et al.: MONARCH 2: Abemaciclib in combination with fulvestrant in women with HR1/HER2 advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol, 2017, 25, s. 2875 2884. 29 Andreé, F. Ciruelos, E. Rubovzsky, G., et al.: Alpelisib for PIK- 3CA-mutated, hormone receptor-positive advanced breast cancer. N Engl J Med, 2019, 380, s. 1929 1940. Aktuální možnosti léčby karcinomu prsu MUDr. Zuzana Bielčiková, Ph.D. Onkologická klinika 1. LF UK a VFN, Praha 1 EBCTCG. Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trial. Lancet, 2019, 393, s. 1440 1452. 2 Masudan, N. Lee, S. J. Ohtani, S., et al.: Adjuvant capecitabine for breast cancer after preoperative chemotherapy. NEJM, 2017, 376,

s. 2147 2159. 3 Blum, J. L. Flynn, P. J. Yothers, G., et al.: Anthracyclines in early breast cancer: the ABC trials USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology). J Clin Oncol, 2017, 35, s. 2647 2655. 4 Ejlertsen, B. Tuxen, M. K. Jakobsen, E. H., et al.: Adjuvant cyclophosphamide and docetaxel with or without epirubicin for early TO- P2A-normal breast cancer: DBCG 07 READ, an open-label, phase iii, randomized trial. J Clin Oncol, 2017, 35, s. 2639 2646. 5 Gluz, O. Nitz, U. Christgen, M., et al.: Five-year results of the prospective Phase III WSG PlanB trial confirm prognostic impact of 21- Gene Recurrence Score in high-risk HR+/HER2 early breast cancer (EBC) patients with 1 3 involved lymph nodes. The Breast, 2017, 32, s. 93. 6 Gray, R., et al.: Extended aromatase inhibitor treatment following 5 or more years of endocrine therapy: A meta-analysis of 22,192 women in 11 randomized trials. SABCS, 2018, abstract G, s. 2 4. 7 Prudence A. F. Pagani, O. Fleming, G. F., et al.: Tailoring adjuvant endocrine therapy for premenopausal breast cancer. NEJM, 2018, 379, s. 122 137. 8 Sparano, J. A. Gray, R. J. Makower, D. F., et al.: Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. NEJM, 2018, 379, s. 111 121. 9 Cardoso, F. van t Veer, L. J. Bogaerts, J., et al.: 70-gene signature as an aid to treatment decisions in early-stage breast cancer. NEJM, 2016, 375, s. 717 729. 10 Gianni, L. Pienkowski, T. Im, Y. H., et al.: Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (Neo- Sphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol, 2012, 13, s. 25 32. 11 Schneeweiss, A. Chia, S. Hickish, T., et al.: Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol, 2013, 24, s. 2278 2284. 12 von Minckwitz, G. Procter, M. De Azambuja, E., et al.: Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. NEJM, 2017, 377, s. 122 131. 13 Martin, M. Holmes, F. A. Ejlertsen, B., et al.: Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, 2017, 8, s. 1688 1700. 14 Von Minckwitz, G. Huang, Ch. S. Mano, M. S., et al.: Trastuzumab emtansine for residual invasive HER2-positive breast cancer. NEJM, 2019, 380, s. 617 628. 15 Tolaney, S. M. Barry, W. T. Guo H., et al.: Seven-year (yr) follow-up of adjuvant paclitaxel (T) and trastuzumab (H) (APT trial) for node-negative, HER2-positive breast cancer (BC). J Clin Oncol, 2017, 35, s. 511. 16 Inno, A. Barni, S. Ghidini, A., et al.: One year versus a shorter duration of adjuvant trastuzumab for HER2-positive early breast cancer: a systematic review and meta-analysis. Breast Cancer Res Treat, 2019, 173, s. 247 254. 17 Ruhstaller, T. Giobbie-Hurder, A. Colleoni, M., et al.: Adjuvant letrozole and tamoxifen alone or sequentially for postmenopausal women with hormone receptor positive breast cancer: long-term follow-up of the BIG 1-98 Trial. J Clin Oncol, 2019, 2, s. 105 114. 18 Cardoso, F. Costa, A. Senkus, E., et al.: 3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3). Breast, 2017, 31, s. 244 259. 19 Finn, R. S. Crown, J. P. Lang I., et al.: The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol, 2015, 16, s. 25 35. 20 Finn, R. S. Martin, M. Rugo, H. S., et al.: Palbociclib and letrozole in advanced breast cancer. NEJM, 2016, 375, s. 1925 1936. 21 Hortobagyi, G. N. Stemmer, S. M. Burris, H. A., et al.: Ribociclib as first-line therapy for HR-positive, advanced breast cancer. NEJM, 2016, 375, s. 1738 1748. 22 Goetz, M. P. Toi, M. Campone, M., et. al.: MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol, 2017, 35, s. 3638 3646. 23 Slamon, D. J. Neven, P. Chia, S., et al.: Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. J Clin Oncol, 2018, 36, s. 2465 2472. 24 Tripathy, D. Im, S. A. Colleoni, M., et al.: Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): A randomized phase 3 trial. Lancet Oncol, 2018, 19, s. 904 915. 25 Im, S. A. Lu, Y. S. Bardia, A., et al.: Overall survival with ribociclib plus endocrine therapy in breast cancer. NEJM, 2019, 381, s. 307 316. 26 Neven, P. Rugo, H. S. Tolaney, S. M., et al.: Abemaciclib for pre/ perimenopausal women with HR+, HER2 advanced breast cancer. J Clin Oncol, 2018, 36, abstrakt 1002. 27 Loibl, S. Rurner, N. C. Ro, J., et al.: Palbociclib combined with fulvestrant in premenopausal women with advanced breast cancer and prior progression on endocrine therapy: PALOMA-3 results. Oncologist, 2017, 22, s. 1028 1038. 28 Robertson, J. F. Bondarenko, I. M. Trishina, E., et al.: Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. Lancet Oncol, 2016, 388, s. 2997 3005. 29 Metha, R. S. Barlow, W. E. Albain, K. S., et al.: Combination anastrozole and fulvestrant in metastatic breast cancer. NEJM, 2012, 367, s. 435 444. 30 Ellis, M. J. Llombart-Cussak, A. Feltl, D., et al.: Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: overall survival analysis from the phase II FIRST Study. J Clin Oncol, 2015, 32, s. 3781 3787. 31 Baselga, J. Campone, M. Piccart, M., et al.: Everolimus in postmenopausal hormone receptor-positive advanced breast cancer. NEJM, 2012, 366, s. 520 529. 32 Andre, F. Ciruelos, E. M. Rubovszky, G., et al.: LBA3_PR: Alpelisib (ALP) + fulvestrant (FUL) for advanced breast cancer (ABC): Results of the phase III SOLAR-1 trial. Ann Oncol, 2018, abstr. LBA3. 33 Sledge, G. W. Toi, M. Neven, P., et al.: MONARCH 2: Abemaciclib in combination with fulvestrant in women with HR+/HER2 advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol, 2017, 35, s. 2875 2884. 34 Cristofanelli, M. Turner, N. C. Bondarenko, I., et al.: Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol, 2016, 17, s. 425 439. 35 Dickler, M. Tolaney, S. M. Rugo, H. S., et al.: MONARCH-1: results from a phase 2 study of abemaciclib, CDK4 and CDK6 inhibitor, as monotherapy, in patients with HR+/HER2 breast cancer, after chemotherapy for metastatic disease. J Clin Oncol, 2016, 34, abstrakt 510. 36 Barroso Sousa, R. Shapiro, G. I. Tolaney, S. M.: Clinical development of the CDK4/6 inhibitors ribociclib and abemaciclib in breast cancer. Breast Care (Basel), 2016, 11, s. 167 173. 37 Varella, L. Abraham, J. Kruse, M., et al.: Revisiting the role of bevacizumab in the treatment of breast cancer. Semin Oncol, 2017, 44, s. 273 285. 38 Schmid, P. Adams, S. Rugo, H. S., et al.: Results from a global, randomised, double-blind, phase 3 study of atezolizumab (atezo) + nab-paclitaxel (nab-p) vs placebo + nab-p in treatment-naive, locally advanced or metastatic triple-negative breast cancer (mtnbc). Ann Oncol, 2018, 29, abstrakt LBA1_PR. 39 Loi, S. Drubay, D. Adams, S., et al.: Tumor-infiltrating lymphocytes and prognosis: a pooled individual patient analysis of early-stage triple-negative breast cancers. J Clin Oncol, 2019, 37, s. 559 569. 40 Robson, M. E. Im, S. Senkus, E., et al.: Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. NEJM, 2017, 377, s. 523 533. 41 Robson, M. E. Tung, N. Conte, P., et al.: OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann Oncol, 2019, 30, s. 558 566. 42 Slamon, D. J. Leyland-Jones, B. Shak, S., et al.: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. NEJM, 2001, 344, s. 783 792. 43 Gelmon, K. Boyle, F. Kaufman, B., et al.: Open-label phase III randomized controlled trial comparing taxane-based chemotherapy (Tax) with lapatinib (L) or trastuzumab (T) as first-line therapy for women with HER2+ metastatic breast cancer: Interim analysis (IA) of NCIC CTG MA.31/GSK EGF 108919. J Clin Oncol, 2012, 30, abstrakt LBA671. 44 Hurvitz, S. A. Andre, F. Jiang, Z., et al.: Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial. Lancet Oncol, 2015, 6, s. 816 829. 45 Baselga, J. Cortez, J. Kim S. B., et al.: Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. NEJM, 2012, 366, s. 109-119. 46 Swain, S. M. Baselga, J. Kim, S. B., et al.: Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. NEJM, 2015, 372, s. 724 734. 47 Romond, E. H. Perey, E. A. Brzant, J., et al.: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. NEJM, 2005, 353, s. 1673 1684. 48 Verma, S. Miles, D. Gianni, L., et al.: Trastuzumab emtansine for HER2-positive advanced breast cancer. NEJM, 2012, 367, s. 1783 1791. 49 Andre, F. O Regan, R. Ozguroglu, M., et al.: Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, doubleblind. Lancet Oncol, 2014, 15, s. 580 591. 50 Harbeck, N. Huang, C. H. S. Hurvitz, S., et al.: Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial. Lancet Oncol, 2016, 17, s. 357 366. 51 Krop, I. E. Kim, S. B. Gonzáles-Martín, A., et al.: Trastuzumab emtansine versus treatment of physician s choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. Lancet Oncol, 2014, 15, s. 689 699. 52 Blackwell, K. L. Burstein, H. J. Storniolo, A. M., et al.: Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol, 2010, 28, s. 1124 1130. 53 Sella, T.: 8 th Annual Fellows Forum in Breast Oncology 2019, přednáška. 54 Marra, A.: 8 th Annual Fellows Forum in Breast Oncology 2019, přednáška. Vliv ribociclibu v kombinaci s endokrinní léčbou na celkové přežití u žen s karcinomem prsu Studie MONALEESA-7 MUDr. Jiří Slíva, Ph.D. Ústav farmakologie 3. LF UK, Praha 1 Caldon, C. E. Daly, R. J. Sutherland, R. L. Musgrove, E. A.: Cell cycle control in breast cancer cells. J Cell Biochem, 2006, 97, s. 261 274. 2 Koboldt, D. C. Fulton, R. S. McLellan, M. D., et al.: Comprehensive molecular portraits of human breast tumours. Nature, 2012, 490, s. 61 70. 3 Zardavas, D. Baselga, J. Piccart, M.: Emerging targeted agents in metastatic breast cancer. Nat Rev Clin Oncol, 2013, 10, s. 191 210. 4 Im, S. A. Lu, Y. S. Bardia, A., et al.: Overall survival with ribociclib plus endocrine therapy in breast cancer. N Engl J Med, 2019, doi: 10.1056/NEJMoa1903765, epub před tiskem. Nemetastatický kastračně rezistentní karcinom prostaty MUDr. Jana Katolická, Ph.D. Onkologicko-chirurgické oddělení FN u sv. Anny v Brně 1 Freedland, S. J. Richhariya, A. Wang, H., et al.: Treatment patterns in patients with prostate cancer and bone metastasis among US community-based urology group practices. Urology, 2012, 80, s. 293 298. 2 Esther, J. Maughan, B. J. Anderson, N., et al.: Management of nonmetastatic castration-resistant prostate cancer: recent advances and future direction. Curr Treat Options in Oncol, 2019, 20, s. 14. 3 Smith, M. R. Saad, F. Chowdhury, S., et al.: Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med, 2018, 378, s. 1408 1418. 4 Hussain, M. Fizazi, K. Saad, F., et al.: Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N Engl J Med, 2018, 378, s. 2465 2474. 5 Fizazi, K. Shore, N. Tammela, T. L., et al.: Darolutamide in nonmetastatic, castration-resistant prostate cancer. N Engl J Med, 2019, DOI: 10.1056/NEJMoa1815671.

6 Beaver, J. A. Kluetz, P. G. Pazdur, R.: Metastasis-free survival: a new end point in prostate cancer trials. N Engl J Med, 2018, 378, s. 2458 2460. 7 Afshar, M. Evison, F. James, N. D., et al.: Shifting paradigms in the estimation of survival for castration resistant prostate cancer: a tertiary academic center experience. Urol Oncol, 2015, 33, s. 338.e1 7. 8 Smith, M. R. M. M. Nair, S. Lawson, J., et al.: Association of metastasis-free survival (MFS) and overall survival (OS) in nonmetastatic castration-resistant prostate cancer (nmcrpc). J Clin Oncol, 2018, 36, abstrakt 5032. Lorlatinib zařazení do aktuální léčebné praxe MUDr. Juraj Kultan Klinika plicních nemocí a tuberkulózy FN a LF UP v Olomouci 1 Robinson, D. R. Wu, Y. M. Lin, S. F.: The protein tyrosine kinase family of the human genome. Oncogene, 2000, 19, s. 5548 5557. 2 Hubbard, S. R. Miller, W. T.: Receptor tyrosine kinases: mechanisms of activation and signaling. Curr Opin Cell Biol, 2007, 19, s. 117 123. 3 Sanz-Ezquerro, J. J. Münsterberg, A. E. Stricker, S.: Editorial: signaling pathways in embryonic development. Front Cell Dev Biol, 2017, 5, s. 76. 4 Bayliss, R. Choi, J. Fennell, D. A., et al.: Molecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugs. Cell Mol Life Sci, 2016, 73, s. 1209 1224. 5 Mathas, S. Kreher, S. Meaburn, K. J., et al.: Gene deregulation and spatial genome reorganization near breakpoints prior to formation of translocations in anaplastic large cell lymphoma. Proc Natl Acad Sci U S A, 2009, 106, s. 5831 5836. 6 Du, X. Shao, Y. Qin, H. F., et al.: ALK-rearrangement in non-smallcell lung cancer (NSCLC). Thorac Cancer, 2018, 9, s. 423 430. 7 Morris, S. W., et al.: Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-hodgkin s lymphoma. Science, 1994, 263, s. 1281 1284. 8 Soda, M. Choi, Y. L. Enomoto, M., et al.: Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature, 2007, 448, s. 561 566. 9 Hallberg, B. Palmer, R. H.: The role of the ALK receptor in cancer biology. An Oncol, 2016, 27, suppl. 3, s. iii4 iii15. 10 Guan, J. Umapathy, G. Yamazaki, Y., et al.: FAM150A and FAM150B are activating ligands for anaplastic lymphoma kinase. Elife, 2015, 4, e09811. 11 Bayliss, R. Choi, J. Fennell, D. A., et al.: Molecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugs. Cell Mol Life Sci, 2016, 73, s. 1209 1224. 12 Lin, J. J. Riely, G. J. Shaw, A. T., et al.: Precision medicine takes on drug resistance. Cancer Discov, 2017, 7, s. 137 155. 13 Chiarle, R. Voena, C. Ambrogio, C., et al.: The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer, 2008, 8, s. 11 23. 14 Sehgal, K. Patell, R. Rangachari, D., et al.: Targeting ROS1 rearrangements in non-small cell lung cancer with crizotinib and other kinase inhibitors. Transl Cancer Res, 2018, 7, suppl. 7, s. S779 S786. 15 Shaw, A. T. Ou, S. H. Bang, Y. J., et al.: Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med, 2014, 371, s. 1963 1971. 16 Hofman, P.: ALK in non-small cell lung cancer (NSCLC) pathobiology, epidemiology, detection from tumor tissue and algorithm diagnosis in a daily practice. Cancers (Basel), 2017, 9, s. 107. 17 Le, T. Gerber, D. E.: ALK alterations and inhibition in lung cancer. Semin Cancer Biol, 2017, 42, s. 81 88. 18 Shaw, A. T. Yeap, B. Y. Mino-Kenudson, M., et al.: Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol, 2009, 27, s. 4247 4253. 19 Yang, P. Kulig, K. Boland, J. M., et al.: Worse disease-free survival in never-smokers with ALK+ lung adenocarcinoma. J Thorac Oncol, 2012, 7, s. 90 97. 20 Barlesi, F. Mazieres, J. Merlio, J. P., et al.: Routine molecular profiling of patients with advanced non-small-cell lung cancer: Results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). Lancet, 2016, 387, s. 1415 1426. 21 Bergethon, K. Shaw, A. T. Ou, S. H., et al.: ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol, 2012, 30, s. 863 870. 22 Warth, A. Muley, T. Dienemann, H., et al.: ROS1 expression and translocations in non-small-cell lung cancer: clinicopathological analysis of 1478 cases. Histopathology, 2014, 65, s. 187 194. 23 Huber, K. V. Salah, E. Radic, B., et al.: Stereospecific targeting of MTH1 by (S)-crizotinib as an anticancer strategy. Nature, 2014, 508, s. 222 227. 24 Kazandjian, D. Blumenthal, G. M. Chen, H. Y., et al.: FDA approval summary: crizotinib for the treatment of metastatic non-small cell lung cancer with anaplastic lymphoma kinase rearrangements. Oncologist, 2014, 19, s. e5 e11. 25 Dostupné z: https://www.ema.europa.eu, vyhlednáno 4. 6. 2019. 26 Shaw, A. T. Dong-Wan, K. Nakagawa, K., et al.: Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med, 2013, 368, s. 2385 2394. 27 Solomon, B. J. Mok, T. Kim, D. W., et al.: First-line crizotinib versus chemotherapy in ALK-positive lung cancer. New Eng J Med, 2014, 371, s. 2167 2177. 28 Sharma, G. G. Mota, I. Mologni, L., et al.: Tumor resistance against ALK targeted therapy-where it comes from and where it goes. Cancers (Basel), 2018, 10, s. 62. 29 Rothenstein, J. M. Chooback, N.: ALK inhibitors, resistance development, clinical trials. Curr Oncol, 2018. 25, suppl. 1, s. S59 S67. 30 Sullivan, I. Planchard, D.: ALK inhibitors in non-small cell lung cancer: the latest evidence and developments. Ther Adv Med Oncol, 2016, 8, s. 32 47. 31 Shaw, A. T. Solomon, B. Lilenbaum, R. C., et al.: Anaplastic lymphoma kinase (ALK) fusion oncogene positive non-small cell lung cancer, dostupné z: https://www.uptodate.com/contents/anaplastic-lymphoma-kinase-alk-fusion-oncogene-positive-non-small-cell-lung-cancer, vyhledáno 4. 6. 2019. 32 Gainor, J. F. Dardaei, L. Yoda, S., et al.: Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer. Cancer Discov, 2016, 6, s. 1118 1133. 33 Shaw, A. T. Friboulet, L. Leshchiner, I., et al.: Resensitization to crizotinib by the lorlatinib ALK resistance mutation L1198F. N Engl J Med, 2016, 374, s. 54 61. 34 Le, T. Gerber, D. E.: ALK alterations and inhibition in lung cancer. Semin Cancer Biol, 2017, 42, s. 81 88. 35 Shaw, A. T. Felip, E. Bauer, T. M., et al.: Lorlatinib in non-smallcell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial. Lancet Oncol, 2017, 18, s. 1590 1599. 36 Solomon, B. J. Besse, B. Bauer, T. M., et al.: Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. Lancet Oncol, 2018, 19, s. 1654 1667. 37 Dostupné z: http://ec.europa.eu/health/documents/community-register/2019/20190506144341/anx_144341_cs.pdf, vyhledáno 17. 6. 2019. 38 Desai, A. Sriwastava, S. Gadgeel, S. M., et al.: New onset myasthenia gravis in a patient with non small cell lung cancer treated with lorlatinib a nowel anti-cancer agent. J Neurol Sci, 2018, 392, s. 100 101. 39 Chabrol, A. Mayenga, M. Hamid, A. M., et al.: Lorlatinib Induced pulmonary arterial hypertension. Lung Cancer, 2018, 120, s. 60 61. 40 Pacheco, J. P. Gao, D. Smith, D., et al.: Natural history and factors associated with overall survival in stage IV ALK-rearranged non-small cell lung cancer. J Thorac Oncol, 2019, 14, s. 691 700. Nový algoritmus léčby pokročilého NSCLC doc. MUDr. Milada Zemanová, Ph.D. Onkologická klinika 1. LF UK a VFN, Praha 1 ÚZIS ČR, NOR ČR 2015, Novotvary 2015, Cancer Incidence 2015 in the Czech Republic. 2 Curran, W. J. Jr. Paulus, R. Langer, C. J., et al.: Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst, 2011, 103, s. 1452 1460. 3 Aupérin, A. LePéchoux, C. Rolland, E., et al.: Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol, 2010, 28, s. 2181 2190. 4 Antonia, S. J. Villegas, A. Daniel, D., et al.; PACIFIC Investigators: Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med, 2018, 379, s. 2342 2350. 5 Mok, T. S. Wu, Y. L. Thongprasert, S., et al.: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med, 2009, 361, s. 947 957. 6 Lee, C. K. Davies, L. Wu, Y. L., et al.: Gefitinib or erlotinib vs chemotherapy for EGFR mutation-positive lung cancer: individual patient data meta-analysis of overal survival. J Natl Cancer Inst, 2017, 109. 7 Yang, J. C. Wu, Y. L. Schuler, M., et al.: Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol, 2015, 16, s. 141 151. 8 Soria, J.-C. Ohe, Y. Vansteenkiste, J., et al.; FLAURA Investigators: Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med, 2018, 378, s. 113 125. 9 Wu, Y. L. Cheng, Y. Zhou, X., et al.: Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cance (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncol, 2017, 18, s. 1454 1466. 10 Kato, T. Seto, T. Nishio, M., et al.: Erlotinib plus bevacizumab phase ll study in patients with advanced non-small-cell lung cancer (JO25567): updated safety results. Drug Saf, 2018, 41, s. 229 237. 11 Mok, T. S. Wu, Y. I. Ahn, M. J., et al.: Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med, 2017, 376, s. 629 640. 12 Solomon, B. J. Mok, T. Kim, D. W., et al.; PROFILE 1014 Investigators: First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med, 2014, 371, s. 2167 2177. 13 Shaw, A. T. Kim, T. M. Crinò, L., et al.: Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol, 2017, 18, s. 874 886. 14 Camidge, D. R. Dziadziuszko, R. Peters, S., et al.: Updated efficacy and safety data and impact of the EML4-ALK fusion variant on the efficacy of alectinib in untreated ALK-positive advanced non-small cell lung cancer in the global phase III ALEX study. J Thorac Oncol, 2019, pii: S1556-0864, s. 30210 30212. 15 Kim, D. W. Tiseo, M. Ahn, M. J., et al.: Brigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-smallcell lung cancer: a randomized, multicenter phase II trial. J Clin Oncol, 2017, 35, s. 2490 2498. 16 Solomon, B. J. Besse, B. Bauer, T. M., et al.: Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. Lancet Oncol, 2018, 19, s. 1654-1667, doi: 10.1016/ S1470-2045(18)30649-1, Epub 6. 11. 2018, erratum in: Lancet Oncol, 2019, 20, e10. 17 Planchard, D. Smit, E. F. Groen, H. J. M., et al.: Dabrafenib plus trametinib in patients with previously untreated BRAF V600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. Lancet Oncol, 2017, 18, s. 1307 1316. 18 Joshi, A. Pande, N. Noronha, V., et al.: ROS1 mutation non-small cell lung cancer access to optimal treatment and outcomes. E Cancer Medical Science, 2019, 13, s. 900. 19 Reck, M. Rodríguez-Abreu, D. Robinson, A. G., et al.; KEY- NOTE-024 Investigators: Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med, 2016, 375, s. 1823 1833. 20 Gandhi, L. Rodríguez-Abreu, D. Gadgeel, S., et al.; KEYNOTE-189 Investigators: Pembrolizumab plus chemotherapy in metastatic nonsmall-cell lung cancer. N Engl J Med, 2018, 378, s. 2078 2092. 21 Reck, M. von Pawel, J. Zatloukal, P., et al.: Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for non squamous non-small-cell lung cancer: AVAiL. J Clin Oncol, 2009, 28, s. 1227 1234. 22 Sculier, J. Pand Moro-Sibilot, D.: First-and second-line therapy for advanced non small cell lung cancer. Eur Respir J, 2009, 33, s. 915 930. 23 Scagliotti, G. V. Parikh, P. Pavel, J., et al.: Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patiens with advanced-stage non small-cell lung cancer. J Clin Oncol, 2008, 26, s. 3543 3551. 24 Lee, D. H.: Treatments for EGFR-mutant non-small-cell lung cancer (NSCLC): The road to a success, paved with failures. Pharmacol Ther, 2017, 174, s. 1 21. 25 Gadgeel, S. Peters, S. Mok, T., et al.: Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) nonsmall-cell lung cancer: CNS efficacy results from the ALEX study. Ann Oncol, 2018, 29, s. 2214 2222. 26 Thatcher, N. Hirsch, F. R. Luft, A. V., et al.; SQUIRE Investigators: Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. Lancet Oncol, 2015, 16, s. 763 774. 27 Gerber, D. E. Schiller, J. H.: Maintenance chemotherapy for advanced non-small-cell lung cancer: new life for an old idea. J Clin